Clinical Trial Search

Primary: Change From Baseline in Acceptability of Implementation Measure (AIM-Imp) Score in SSP at Month 12 — 3.8; 3.9; 0.28; 0.33 Scores on a scale

Primary: Clearance of Benralizumab — 0.156 liter (L) per day

Primary: Overall Survival (OS) — 277.0; 252.0 days — p=0.6063

Primary: VAS Score at 1 Hour at Rest — 5.0; 3.0 score on a scale — p=0.54

Primary: Overall Survival (OS) — 10.3; 9.2 Months — p=0.025

Primary: Percentage of Participants Achieving at Least a 20% Reduction From Baseline Hour 0 IOP While on the Same Number or Fewer IOP Lowering Medications at Month 12 — 80.5…

Primary: WOMAC Pain Score (Change From Baseline at Week 16) — -1.74; -2.96; -1.78; -2.12 units on a scale — p=<0.001

Primary: Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score — -16.2; -16.9; -14.5 score on a scale — p=0.021

Primary: Reduction in Days of Headache Pain With Treatment of Memantine or Valproate in the Preventive Management of Episodic Migraine. — 5.35; 5.31; 0.77; 0.93 Migraine days by…

Primary: Geometric Mean Concentrations (GMCs) of Binding Antibody Levels Against the Ebola Virus Glycoprotein (EBOV GP) as Measured by Enzyme-linked Immunosorbent Assay (ELISA)…

Primary: Galectin-3 — 9570.91; 9266.7; 9539.21; 8098.78 pg/ml

Primary: Percentage of Participants With Suppression of Peak Gonadotropin-releasing Hormone Agonist (GnRHa)-Stimulated Luteinizing Hormone (LH) to Less Than 4 mlU/mL at Week 24…

Primary: Percentage of Participants With Local Reactions Within 7 Days After Dose 1: Primary Study Population — 20.7; 22.7; 4.5; 4.8 Percentage of participants

Primary: Rate of Objectively Confirmed VTE Complications — 7; 4 Participants — p=0.0252

Primary: Cohort A: Percentage of Participants Who Have a Symptomatic RT-qPCR Confirmed SARS-CoV-2 Infection (Broad-term) During the EAP — 7.8; 1.4 Percentage of Participants…